The collaboration, through which Hummingbird will have access to Tempus' TIME Trial Network, is focused on advancing the HER3-targeted agent, HMBD-001.
Reveal Genomics plans to have assays available within three years, and is eager to partner with pharmaceutical and diagnostics companies to fulfill its vision.
The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.
The data add to growing evidence supporting the use of HER2 therapy across solid tumors, though researchers find a difficult path to a tissue-agnostic approval.
Exome sequences from dozens of cervical cancer tumor or primary cell line samples revealed recurrent alterations affecting ERBB2/HER2 and PIK3CA pathways.
An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.
Meeting presentations supported tweaking the clinical interpretation of Genomic Health's Oncotype DX and bolstered Biotheranostics' Breast Cancer Index.
Studies presented at the AACR meeting demonstrated how the registry can be used to evaluate how cancer patients with rare tumor markers respond to treatments.
